We found that primary glioma patients with higher-than-median expression levels of either SOCS1, SOCS3 or RNF7 had an unfavorable prognosis compared to those with lower-than-median expression levels (P < 0.0001) (Figure 5). The gene discussed is SOCS1; the disease is glioma.